Heterologous Human Immunodeficiency Virus Type 1 Priming-Boosting Immunization Strategies Involving Replication-Defective Adenovirus and Poxvirus Vaccine Vectors-Reference-Cited by-同舟云学术

Heterologous Human Immunodeficiency Virus Type 1 Priming-Boosting Immunization Strategies Involving Replication-Defective Adenovirus and Poxvirus Vaccine Vectors

Published:2004-10-15 Issue:20 Volume:78 Page:11434-11438
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Casimiro Danilo R.¹,Bett Andrew J.¹,Fu Tong-ming¹,Davies Mary-Ellen¹,Tang Aimin¹,Wilson Keith A.¹,Chen Minchun¹,Long Romnie¹,McKelvey Troy¹,Chastain Michael¹,Gurunathan Sanjay²,Tartaglia Jim³,Emini Emilio A.¹,Shiver John¹

Affiliation:

1. Department of Viral Vaccine Research, Merck Research Laboratories, Merck & Co., West Point

2. Aventis-Pasteur, Inc., Swiftwater, Pennsylvania

3. Aventis-Pasteur, Ltd., Toronto, Ontario, Canada

Abstract

ABSTRACT We compared the human immunodeficiency virus type 1 (HIV-1)-specific cellular immune responses elicited in nonhuman primates by HIV-1 gag -expressing replication-defective adenovirus serotype 5 (Ad5) or poxvirus vectors, used either alone or in combination with each other. The responses arising from a heterologous Ad5 priming-poxvirus boosting regimen were significantly greater than those elicited by homologous regimens with the individual vectors or by a heterologous poxvirus priming-Ad5 boosting regimen. The heterologous Ad5 priming-poxvirus boosting approach may have potential utility in humans as a means of inducing high levels of cellular immunity.

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/JVI.78.20.11434-11438.2004

Reference23 articles.

1. CD8 + Lymphocytes from Simian Immunodeficiency Virus-Infected Rhesus Macaques Recognize 14 Different Epitopes Bound by the Major Histocompatibility Complex Class I Molecule Mamu-A*01: Implications for Vaccine Design and Testing

2. Critical Role for Env as well as Gag-Pol in Control of a Simian-Human Immunodeficiency Virus 89.6P Challenge by a DNA Prime/Recombinant Modified Vaccinia Virus Ankara Vaccine

3. Reduction of Simian-Human Immunodeficiency Virus 89.6P Viremia in Rhesus Monkeys by Recombinant Modified Vaccinia Virus Ankara Vaccination

4. Recombinant Vaccine-Induced Protection against the Highly Pathogenic Simian Immunodeficiency Virus SIV mac251 : Dependence on Route of Challenge Exposure

5. Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines;Toxins;2023-09-08

2. Viral vector vaccines;Current Opinion in Immunology;2022-08

3. The use of adenoviral vectors in gene therapy and vaccine approaches;Genetics and Molecular Biology;2022

4. Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials;PLOS Pathogens;2021-11-29

5. Recombinant protein vaccines, a proven approach against coronavirus pandemics;Advanced Drug Delivery Reviews;2021-03